Literature DB >> 11279754

Inhaled vs oral steroids for adults with chronic asthma.

B Mash1, A Bheekie, P W Jones.   

Abstract

OBJECTIVES: To determine therapeutically equivalent doses of inhaled versus oral steroids for adults with chronic asthma. SEARCH STRATEGY: The Cochrane Airways Group trials register was searched using the terms: (drug delivery systems OR ((nebuli* OR inhal* OR MDI) AND oral*)) AND ( steroid* OR corticosteroid* OR glucocorticoid* OR beclomethasone OR betamethasone OR fluticasone OR cortisone OR dexamethasone OR hydrocortisone OR prednisolone OR prednisone OR triamcinolone). SELECTION CRITERIA: Randomised controlled trials were selected of at least 4 weeks duration and included patients over the age of 15 years with chronic asthma. Trials compared inhaled steroids and oral prednisolone or prednisone; where the maximum dose for inhaled steroids was 2000 mcg/day and prednisolone 60 mg (on alternate days). DATA COLLECTION AND ANALYSIS: Two independent reviewers screened 1285 titles and abstracts from the electronic search, bibliography searches and other contacts. Of these, 10 trials met previously defined inclusion criteria. Two reviewers independently extracted study characteristics, and outcome measures. MAIN
RESULTS: All trials were small and no data could be pooled. Carry-over effects were present in at least one cross-over trial. Data from six trials produced the same pattern, in which prednisolone 7.5-12 mg/day appeared to be as effective as inhaled steroid 300-2000 mcg/day. In two trials, inhaled steroid 300-400 mcg/day was more effective than prednisolone 5 mg/day. All doses of inhaled steroid appeared to be more effective than alternate day doses of prednisolone up to 60 mg on alternate days. Side-effect data were reported too variably to permit comparisons. A 30% incidence was reported in one study in patients receiving prednisolone 5 mg/day, none were reported in patients on inhaled steroids. A further search was conducted in October 2000 which yielded no further trials. REVIEWER'S
CONCLUSIONS: A daily dose of prednisolone 7.5-10 mg/day appears to be equivalent to moderate-high dose inhaled corticosteroids. Side-effects may be present on low doses, so if there is no alternative to oral steroids, the lowest effective dose should be prescribed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279754     DOI: 10.1002/14651858.CD002160

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

1.  Treatment of naturally occurring asthma with inhaled fluticasone or oral prednisolone: A randomized pilot trial.

Authors:  Michael Verschoor-Kirss; Elizabeth A Rozanski; Claire R Sharp; Trisha J Oura; Ashley Egan; Perry Bain; Joyce Knoll
Journal:  Can J Vet Res       Date:  2021-01       Impact factor: 1.310

2.  The Saudi Initiative for Asthma.

Authors:  Mohamed S Al-Moamary; Mohamed S Al-Hajjaj; Majdy M Idrees; Mohamed O Zeitouni; Mohammed O Alanezi; Hamdan H Al-Jahdali; Maha Al Dabbagh
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

Review 3.  An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses.

Authors:  Chris D Bailey; Richard Wagland; Rasha Dabbour; Ann Caress; Jaclyn Smith; Alex Molassiotis
Journal:  BMC Pulm Med       Date:  2010-12-09       Impact factor: 3.317

4.  New therapies and management strategies in the treatment of asthma: patient-focused developments.

Authors:  Joshua Agbetile; Ruth Green
Journal:  J Asthma Allergy       Date:  2010-12-30

Review 5.  Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.

Authors:  John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin
Journal:  Respirology       Date:  2021-09-29       Impact factor: 6.175

6.  Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification.

Authors:  C Heneghan; C Blacklock; R Perera; R Davis; A Banerjee; P Gill; S Liew; L Chamas; J Hernandez; K Mahtani; G Hayward; S Harrison; D Lasserson; S Mickan; C Sellers; D Carnes; K Homer; L Steed; J Ross; N Denny; C Goyder; M Thompson; A Ward
Journal:  BMJ Open       Date:  2013-07-06       Impact factor: 2.692

Review 7.  Ciclesonide versus placebo for chronic asthma in adults and children.

Authors:  P Manning; P G Gibson; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 8.  Ciclesonide versus other inhaled steroids for chronic asthma in children and adults.

Authors:  P Manning; P G Gibson; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications.

Authors:  Gillian E Caughey; Adrian K Preiss; Agnes I Vitry; Andrew L Gilbert; Elizabeth E Roughead
Journal:  Diabetes Care       Date:  2013-06-04       Impact factor: 19.112

Review 10.  Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.

Authors:  Jens Markus Borghardt; Charlotte Kloft; Ashish Sharma
Journal:  Can Respir J       Date:  2018-06-19       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.